N-(5-bromothiazol-2-yl)-1,1-diphenylmethanimine | 498574-68-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-bromothiazol-2-yl)-1,1-diphenylmethanimine
• 英文别名: 5-bromo-N-(diphenylmethylene)-1,3-thiazol-2-amine；5-broMo-N-(diphenylMethylene)thiazol-2-aMine；N-(5-bromo-1,3-thiazol-2-yl)-1,1-diphenylmethanimine
• CAS: 498574-68-8
• 化学式: C₁₆H₁₁BrN₂S
• 分子量: 343.247
• InChiKey: PFZJNAYIFUAPPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(5-bromothiazol-2-yl)-1,1-diphenylmethanimine 、 4-三氟甲氧基苯硼酸 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 以81%的产率得到5-[4-(trifluoromethoxy)phenyl]thiazol-2-amine
  参考文献：
  名称：

  EP3741757

  摘要：

  公开号：
• 作为产物：
  描述：

  二苯甲酮亚胺 、 2-氨基-5-溴-噻唑氢溴酸盐 以 1,2-二氯乙烷 为溶剂， 反应 18.0h， 以to give 37.2 g of solid的产率得到N-(5-bromothiazol-2-yl)-1,1-diphenylmethanimine
  参考文献：
  名称：

  Therapeutic use of acylaminothiazole derivatives

  摘要：

  本发明揭示和声明了一种与普通公式（I）相对应的化合物的治疗用途：其中，X、R1、R2、R3、R4、R5、R5'、R6和n如本文所述。

  公开号：

  US07879889B2

文献信息

• Acylaminothiazole derivatives, their preparation and their therapeutic use
  申请人：Despeyroux Pierre

  公开号：US20060052426A1

  公开（公告）日：2006-03-09

  Compound corresponding to the general formula (I): in which, X represents an oxygen or sulphur atom; R 1 represents a C 1-10 alkyl group optionally substituted, a C 3-7 cycloalkyl, thienyl, pyridinyl or pyrimidinyl group; the thienyl groups being optionally substituted; the phenyl group being optionally substituted; R 2 represents a C 1-6 alkyl group optionally substituted, a C 3-7 cycloalkyl, piperidinyl, phenyl or pyridinyl group; the C 3-7 cycloalkyl and piperidinyl groups being optionally substituted; the phenyl and pyridinyl groups being optionally substituted; R 3 represents a hydrogen atom or a C 1-6 alkyl group optionally substituted with a C 3-7 cycloalkyl group; R 4 represents a hydrogen atom or a C 1-6 alkyl group; R 5 and R 5′ represent, independently of each other, a hydrogen or halogen atom, a hydroxyl or C 1-3 alkyl group; or R 5 and R 5′ form together an oxo or oxime group such as: where R 7 represents a hydrogen atom or a C 1-3 alkyl; n represents an integer ranging from 0 to 3; and R 6 represents, independently of each other when n=2 or 3, a hydrogen or halogen atom, a hydroxyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 fluoroalkyl or C 1-3 fluoroalkoxy group; in the form of a base, of an addition salt with an acid, of a hydrate or of a solvate. therapeutic application.

  对应于一般公式（I）的化合物：其中，X代表氧原子或硫原子；R1代表一个C1-10烷基基团，可选择性地取代，一个C3-7环烷基，噻吩基，吡啶基或嘧啶基团；噻吩基可选择性取代；苯基可选择性取代；R2代表一个C1-6烷基基团，可选择性地取代，一个C3-7环烷基，哌啶基，苯基或吡啶基团；C3-7环烷基和哌啶基可选择性取代；苯基和吡啶基可选择性取代；R3代表氢原子或一个C1-6烷基基团，可选择性地取代为C3-7环烷基团；R4代表氢原子或一个C1-6烷基基团；R5和R5'分别代表氢原子或卤素原子，羟基或C1-3烷基基团；或者R5和R5'共同形成一个醛基或肟基，如：其中R7代表氢原子或一个C1-3烷基；n表示一个介于0到3之间的整数；R6代表，当n=2或3时，独立地一个氢或卤素原子，一个羟基，C1-3烷基，C1-3烷氧基，C1-3氟烷基或C1-3氟烷氧基团；以碱、与酸形成的加合盐、水合物或溶剂化合物的形式。治疗应用。
• Acylaminothiazole derivatives, their preparation and therapeutic use
  申请人：——

  公开号：US20040171643A1

  公开（公告）日：2004-09-02

  The invention concerns a compound of general formula (I), wherein: X represents an oxygen or sulphur atom; R 1 represents, independently of each other when n=2 or 3, a halogen atom, a hydroxy, a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy, a trifluoromethyl, a trifluoromethyloxy or a methylenedioxy; R 2 represents a C 1 -C 6 alkyl group optionally substituted, a C 3 -C 7 cycloalkyl, piperidinyl or phenyl group, the C 3 -C 7 cycloalkyl, piperidinyl or phenyl groups being optionally substituted; R 3 represents a hydrogen atom or a C 1 -C 6 alkyl group optionally substituted; R 4 represents a hydrogen atom or a C 1 -C4 alkyl group; and R 5 and R 5′ represent, independently of each other, a hydrogen atom, a hydroxy, a halogen atom, a C 1 -C 3 alkyl group, or R 5 and R 5′ form together an oxo group; R 6 represents a hydrogen atom, a halogen atom, a C 1 -C 3 alkyl, a C 1 -C 3 alkoxy, a trifluoromethyl, or a trifluoromethoxy; in the form of a base, addition to an acid, hydrate or solvate. The invention is applicable in therapy. 1

  这项发明涉及一种通式(I)的化合物，其中：X代表氧或硫原子；R1代表，当n=2或3时独立地表示卤素原子、羟基、C1-C3烷基、C1-C3烷氧基、三氟甲基、三氟甲氧基或亚甲二氧基；R2代表可选地取代的C1-C6烷基基团、C3-C7环烷基、哌啶基或苯基，其中C3-C7环烷基、哌啶基或苯基可选地取代；R3代表氢原子或可选地取代的C1-C6烷基基团；R4代表氢原子或C1-C4烷基基团；R5和R5′独立地表示氢原子、羟基、卤素原子、C1-C3烷基基团，或者R5和R5′一起形成醛基；R6代表氢原子、卤素原子、C1-C3烷基、C1-C3烷氧基、三氟甲基或三氟甲氧基；以碱、酸盐、水合物或溶剂化合物的形式存在。该发明适用于治疗。
• ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
  申请人：DE COINTET Paul

  公开号：US20080058380A1

  公开（公告）日：2008-03-06

  The invention relates to a compound corresponding to the general formula (I): wherein, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ and R 6 are as defined herein. More specifically, this invention relates to intermediates to prepare a compound of formula (I) as well as its utility in treating a variety of diseases including Alzheimer's disease and Parkinson's disease.

  本发明涉及与通式（I）相对应的化合物：其中，X，R1，R2，R3，R4，R5，R5'和R6如本文所定义。更具体地，本发明涉及制备通式（I）化合物的中间体，以及其在治疗包括阿尔茨海默病和帕金森病在内的多种疾病中的用途。
• Therapeutic Use of Acylaminothiazole Derivatives
  申请人：DESPEYROUX Pierre

  公开号：US20090253753A1

  公开（公告）日：2009-10-08

  The present invention discloses and claims therapeutic uses of a compound corresponding to the general formula (I): Wherein, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 6 and n are as described herein.

  本发明揭示和声明了一种与一般式(I)相对应的化合物的治疗用途：其中，X、R1、R2、R3、R4、R5、R5'、R6和n如本文所述。
• DIHYDROINDOLIZINONE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3741757A1

  公开（公告）日：2020-11-25

  It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.

  本发明的目的是提供一种能够有效诱导多能干细胞分化为胰岛素分泌细胞的新化合物。本发明的目的通过由式（I）代表的化合物来实现： 其中 R1、R2、R3、n 和 A 分别具有与描述中所定义的相同含义，或其盐。